The PSMC5 (Proteasome 26S Subunit, ATPase 5) antibody is a crucial tool for studying the 26S proteasome, a multi-subunit complex responsible for targeted protein degradation via the ubiquitin-proteasome system (UPS). PSMC5. also known as Rpt6. is one of six AAA-ATPase subunits within the 19S regulatory particle of the 26S proteasome. It plays a vital role in substrate recognition, unfolding, and translocation into the proteolytic core (20S particle). Research on PSMC5 is significant in understanding cellular protein homeostasis, stress responses, and diseases linked to proteasome dysfunction, such as cancer, neurodegenerative disorders, and autoimmune conditions.
Antibodies targeting PSMC5 are widely used in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to assess proteasome composition, activity, and localization. They help investigate how PSMC5 expression or mutations correlate with disease progression or drug resistance, particularly in contexts where proteasome inhibitors (e.g., bortezomib) are used therapeutically. Commercial PSMC5 antibodies are typically raised against specific epitopes, with validation in diverse species and cell lines. Researchers rely on these antibodies to explore UPS-related mechanisms, offering insights into therapeutic targeting of proteostasis pathways.